TY -的T1 -值得信赖的严重程度与指导方针thma thanks to the ERS and ATS JF - European Respiratory Journal JO - Eur Respir J SP - 315 LP - 318 DO - 10.1183/09031936.00191113 VL - 43 IS - 2 AU - Brusselle, Guy G. AU - Kraft, Monica Y1 - 2014/02/01 UR - //www.qdcxjkg.com/content/43/2/315.abstract N2 - Although severe asthma is estimated to be present in less than 10% of all asthmatics, these patients have the greatest morbidity and consume an overwhelming proportion of healthcare costs [1]. There have also been challenges defining the disease in terms of severity and control, characteristics which both lead to increased morbidity and mortality. Thus, the greatest unmet need in asthma care is in the severe asthma arena, where heterogeneity with regard to clinical presentation and course has posed therapeutic challenges. The identification of clinical and molecular phenotypes, as discussed in this version of the severe asthma guidelines, moves the field forward and will ultimately lead us to more personalised therapy. These guidelines describe the definition of severe asthma and provide recommendations for an approach to diagnostics and therapeutics given the data available today.Clinical practice guidelines aim to help clinicians and healthcare professionals to make evidence-based decisions about the optimal care for patients [2]. In the past decade, major progress has been made in the methodology and the science of developing guidelines [3]. In contrast to narrative reviews or expert consensus-based clinical position statements (also called “strategic documents”), the development of guidelines requires that the evidence is appraised in a comprehensive and systematic manner and that the recommendations for practice are provided in a transparent manner [3, 4]. The Institute of Medicine has published standards for trustworthy guidelines, providing recommendations on several crucial domains in the development process including transparency, panel composition and conflict of interest [4–6]. Importantly, funders should not play a role in the development, and guideline panels should be multidisciplinary and include patients and/or patient advocates [6, 7]. For the literature review and the grading of recommendations, a systematic approach is … ER -